After a 15-year hiatus, several new antiepileptic drugs have been approved or are under Food and Drug Administration investigation for use in the United States. This article reviews four of these new drugs—felbamate, gabapentin, lamotrigine, and vigabatrin. Although these drugs have been primarily developed for use in adults with partial seizures, they will also likely be used in children with partial epilepsy. Pediatric experience with several of these drugs has demonstrated safety and efficacy in other seizure types and epilepsy syndromes. These drugs will be an important addition to the therapeutic armamentarium for pediatric epilepsy. Additional studies are needed to fully explore the safety and efficacy of these drugs in a variety of pediatric epilepsies and to compare them to existing antiepileptic drugs. (J Child Neurol 1994;9(Suppl):S33-S45).
Get full access to this article
View all access options for this article.
References
1.
Locock C.: Discussion of paper by E.H. Siveking. Analysis of fifty-two cases of epilepsy observed by the author. Lancet1857;1:527-528.
2.
Gowers WR: Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms, and Treatment, 2nd ed. London , Churchill, 1901, p 267.
3.
Conseil de l'Europe: Clinical Trials in Children: Amended Agreed Draft by Efficacy Working Party for CPMP . Brussels, June 1987.
4.
Swinyard EA, Woodhead JH, White HS, et al: Experimental selection, quantification, and evaluation of anticonvulsants , in Levy RH, Dreifuss FE, Mattson RH, et al (eds): Antiepileptic Drugs, 3rd ed. New York, Raven Press, 1989, pp 85-102.
5.
Kupferberg HJ : Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia1989;30(Suppl 1):S51-S56.
6.
Porter RJ, Cereghino JJ, Gladding GD, et al: Antiepileptic drug development program. Cleve Clin Q1984;51:293-305.
7.
Rogowski MA, Porter RJ: Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev1990;42: 223-285.
8.
Macdonald RL , Meldrum BS: Principles of antiepileptic drug action , in Levy RH, Dreifuss FE, Mattson RH, et al (eds): Antiepileptic Drugs, 3rd ed. New York, Raven Press, 1989, pp 59-83.
9.
McCabe RT , Wasterlain CG, Kucharcyk N., et al: Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther1993 ;264:1240-1252.
10.
Swinyard EA , Sofia RD, Kupferberg HJ: Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia1986;27: 27-34.
11.
Sofia RD, Kramer L., Perhac JL, et al: Felbamate. Epilepsy Res1991 ; (Suppl 3):103-108.
12.
Wallace Laboratories: Investigational Drug Brochure. Cranbury, NJ, Carter-Wallace , 1989.
13.
Graves NM, Ludden TM, Holmes GB, et al: Pharmacokinetics of felbamate, a novel antiepileptic drug: Application of mixed-effect modeling to clinical trials. Pharmacotherapy1989;9: 372-376.
14.
Graves NM, Holmes GB, Fuerst RH, et al: Effect of felbamate on phenytoin and carbamazepine serum concentrations . Epilepsia1989;30:225-229.
15.
Albani F., Theodore WH, Washington P., et al: Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia1991;32:130-132.
Leppik IE, Dreifuss FE, Pledger GW, et al: Felbamate for partial seizures: Results of a controlled clinical trial. Neurology1991;41:1785-1789.
18.
Theodore WH , Raubertas RF, Porter JR, et al: Felbamate: A clinical trial for complex partial seizures. Epilepsia1991;32: 392-397.
19.
Sachdeo R., Kramer LD, Rosenberg A., et al: Felbamate monotherapy: Controlled trial in patients with partial onset seizures. Ann Neurol1992;32:386-392.
20.
Bourgeois B. , Leppik IE, Sackellares JC, et al: Felbamate: A double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology1993;43:693-696.
21.
Faught E., Sachdeo RC, Remler MP, et al: Felbamate monotherapy for partial-onset seizures: An active-control trial. Neurology1993;43:688-692.
22.
Devinsky O. , Faught E., Wilder BJ, et al: Felbamate monotherapy trial in patients undergoing surgical evaluation of partial seizures. Epilepsia1993;34(Suppl 6):69.
23.
Felbamate Study Group in Lennox-Gastaut syndrome : Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med1993 ;328:29-33.
24.
Devinsky O. , Kothari M., Savino L., et al: Felbamate for refractory absence seizures . J Epilepsy, in press.
25.
Carmant L., Kramer U., Holmes G., et al: Felbamate is effective against intractable partial seizures . Epilepsia1993;34(Suppl 6): 99.
26.
Espe-Lillo J., Ritter FJ, Frost MD: Safety and efficacy of felbamate in treatment of infantile spasms. Epilepsia1993;34(Suppl 6):110.
27.
Ritter FJ, Bettis DB, Penovich PE: Dramatic response to felbamate of refractory epilepsy in the syndrome of gelastic seizures and hypothalamic hamartoma. Epilepsia1993;34(Suppl 6):140.
28.
Mattson RH, Cramer JA, Collins JF, et al: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med1985;331:145-151.
29.
Vollmer KO, von Hodenberg A., Kolle EU: Pharmacokinetics and metabolism of gabapentin in rat, dog and man . Arzneimittelforschung1986;36:830-839.
30.
Taylor CP: Mechanism of action of new anti-epileptic drugs, in Chadwick D (ed): New Trends in Epilepsy Management: The Role of Gabapentin. London, Royal Society of Medicine, 1993, pp 13-40.
31.
Suman-Chauhan N., Webdale L., Hill DR, et al: Characterization of [3H]-gabapentin binding to a novel site in rat brain: Homogenate binding studies. Eur J Pharmacol1993;244:293-301.
32.
Hill DR, Suman-Chauhan N., Woodruff GN: Localization of [3H]-gabapentin binding to a novel site in rat brain: Autoradiographic studies. Eur J Pharmacol1993;244:303-309.
33.
Chadwick D.: The role of gabapentin in epilepsy management, in Chadwick D (ed): New Trends in Epilepsy Management: The Role of Gabapentin. London, Royal Society of Medicine, 1993, pp 59-65.
34.
Richens A.: Clinical pharmacokinetics of gabapentin, in Chadwick D (ed): New Trends in Epilepsy Management: The Role of Gabapentin. London, Royal Society of Medicine, 1993, pp 41-46.
35.
Busch JA, Radulovic LL, Bockbrader HN, et al: Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects. Pharm Res1992 ;9(Suppl 10):S315.
36.
Tuerck D., Vollmer KO, Bockbrader HN, et al: Dose-linearity of the new anti-convulsant drug gabapentin after multiple oral doses. Eur J Clin Pharmacol1989;36:A310.
37.
Graves NM, Holmes GB, Leppik IE, et al: Pharmacokinetics of gabapentin in patients treated with phenytoin . Pharmacotherapy1989;9:196.
38.
Graves NM, Leppik IE, Wagner ML, et al: Effect of gabapentin on carbamazepine levels. Epilepsia1990;31:644.
39.
Hooper WD, Kavanagh MC, Herkes GK, et al: Lack of a pharmacokinetic interaction between phenobarbital and gabapentin. Br J Clin Pharmacol1991;31:171-174.
40.
Basim M., Uthman EJ, Hammond EJ, et al: Absence of gabapentin and valproate interaction: An evoked potential and pharmacokinetic study. Epilepsia1990;31:645.
41.
US Gabapentin Study Group 5: Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology1993;43:2292-2298.
42.
Crawford P. , Ghadali E., Lane R., et al: Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry1987 ; 50:682-686.
43.
UK Gabapentin Study Group: Gabapentin in partial epilepsy. Lancet1990 ;335:1114-1117.
44.
Abou-Khalil B., Shellenberger MK, Anhut H.: Two open-label, multicenter studies of the safety and efficacy of gabapentin in patients with refractory epilepsy. Epilepsia1992;33:77.
45.
Schear MJ, Weiner JA, Rowan AJ: Long-term efficacy of gabapentin in the treatment of partial seizures . Epilepsia1991; 32:6.
46.
Foot M., Wallace J.: Gabapentin. Epilepsy Res1991; (Suppl 3): 109-114.
47.
Browne TR: Efficacy and safety of gabapentin, in Chadwick D (ed): New Trends in Epilepsy Management: The Role of Gabapentin . London, Royal Society of Medicine , 1993, pp 47-57.
Sander JW, Patsalos PN: An assessment of serum and red blood cell folate concentrations in patients with epilepsy or lamotrigine therapy. Epilepsy Res1992;13:89-92.
50.
Miller AA, Wheatley P., Sawyer DA, et al: Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia1986;27:483-489.
51.
Leach MJ, Baxter MG, Critchley MA: Neurochemical and behavioral aspects of lamotrigine. Epilepsia1991;32(Suppl 2): S4-S8.
52.
Lamb RJ, Leach MJ, Miller AA, et al: Anticonvulsant profile in mice of lamotrigine, a novel anticonvulsant . Br J Pharmacol1985;85:366P.
53.
Wheatley PL , Miller AA: Effects of lamotrigine on electrically induced afterdischarge duration in anaesthetized rat, dog, and marmoset. Epilepsia1989;30:34-40.
54.
Investigator's Brochure—Lamictal (Lamotrigine). Research Triangle Park, NC, Burroughs Wellcome , 1993.
55.
Yuen AWC , Peck AW: Lamotrigine pharmacokinetics: Oral and IV infusion in man, abstract. Br J Clin Pharmacol1988;26:242.
56.
Cohen AF, Land GS, Breimer DD, et al: Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther1987;42:535-541.
57.
Gram L., Larsson OM, Johnsen A., et al: Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol1989;27:135-175.
58.
Yau MK, Adams MA, Wargin WA, et al: A single dose and steady-state pharmacokinetic study of lamotrigine in healthy male volunteers. Presented at the Third InternationalCleveland Bethel Epilepsy Symposium, Cleveland , June 1992.
59.
Rey E., Vauzelle F., Pons G., et al: Pharmacokinetics of lamotrigine in young epileptic children, abstract. Presented at the Fifth World Conference on Clinical Pharmacology and Therapeutics. Yokohama, Japan, July 1992.
60.
Binnie CD, Van Emde Boas W., Kasteleijn-Nolste-Trenite DGA , et al: Acute effects of lamotrigine (BW 430c) in persons with epilepsy . Epilepsia1986;27:248-254.
61.
Jawad S., Yuen WC, Peck AW, et al: Lamotrigine: Single dose pharmacokinetics and initial one week experience in refractory epilepsy. Epilepsy Res1987;1:194-201.
62.
Binnie CD, Van Wieringen A., Meijer JWA, et al: Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res1989;4:222-229.
63.
Jawad S., Richens A., Goodwin G., et al: Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia1989;30:356-363.
64.
Sander Jwas , Patsalos PN, Oxley JR, et al: A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res1990;6:221-226.
65.
Loiseau P., Yuen AWC, Duche B., et al: A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures . Epilepsy Res1990;7:136-145.
66.
Schapel GJ, Beran RG, Vajda FJE, et al: Double-blind, placebo-controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry1993;56:448-453.
67.
Matsuo F., Bergen D., Faught E., et al: Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology1993;43:2284-2291.
68.
Schachter S. , Leppik I., Matsuo F., et al: A multicenter, placebo-controlled evaluation of the safety of lamotrigine (Lamictal) as add-on therapy in outpatients with partial seizures, abstract. Epilepsia1992;33(Suppl 3):119.
69.
Risner ME: Multicenter, double-blind, placebo-controlled, add-on, cross-over study of lamotrigine (Lamictal) in epileptic outpatients with partial seizures, abstract . Epilepsia1990;31: 619-620.
70.
Betts T.: Clinical uses of lamotrigine. Seizure1992 ;1:3-6.
71.
Dulac O., Withers RM, Yuen AWC: Add-on lamotrigine in pediatric patients with treatment-resistant epilepsy, abstract. Epilepsia1991;32(Suppl 1):95.
72.
Hosking G., Spencer SC: Lamotrigine as add-on therapy in pediatric patients with treatment-resistent epilepsy: An overview, abstract. Epilepsia1993;34(Suppl):66.
73.
Messenheimer J., Ramsay RE, Willmore LJ, et al: Lamotrigine therapy for partial seizures: A multicenter placebo-controlled, double-blind, cross-over trial. Epilepsia1994;35:113-121.
74.
Richens A., Yuen AWC: Overview of the clinical efficacy of lamotrigine. Epilepsia1991;32(Suppl 2):513-516.
75.
Ben-Menachem E., Persson LI, Schechter PJ, et al: The effect of different treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol1989;27: 79S-855.
76.
Riekkinen PJ , Ylinen A., Halonen T., et al: Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmcacol1989;27:87S-94S.
77.
Gram L.: Potential antiepileptic drugs: Lamotrigine, in Levy RH, Dreifuss FE, Mattson RH, et al (eds): Antiepileptic Drugs , 3rd ed. New York, Raven Press, 1989, pp 947-953.
Grant SM, Heel RC: Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs1991;41:889-926.
80.
Ylinen A., Sivenius J., Pitkanen A., et al: Gamma-vinyl GABA (vigabatrin) in epilepsy: Clinical, neurochemical, and neurophysiologic monitoring in epileptic patients. Epilepsia1992; 33:917-922.
81.
Richens A.: Potential antiepileptic drugs: Vigabatrin, in Levy RH, Dreifuss FE, Mattson RH, et al (eds): Antiepileptic Drugs , 3rd ed. New York, Raven Press, 1989, pp 937-946.
82.
Graham D.: Neuropathology of vigabatrin. Br J Clin Pharmacol1989;27(Suppl 1):43S-45S.
83.
Butler WH: The neuropathology of vigabatrin. Epilepsia1989; 30:515-517.
84.
Paljarvi L. , Vapalahti M., Sivenius J., et al: Vigabatrin vacuoles in humans: Neuropathologic findings in five patients with vigabatrin treatment . Neurology1990;40:157.
Hammond EJ, Wilder BJ: Effects of gamma-vinyl GABA on human pattern evoked visual potentials . Neurology1985;35: 1801-1803.
87.
Browne TR, Mattson RH, Penry JK, et al: Vigabatrin for refractory complex partial seizures: Multicenter single-blind study with long-term follow-up. Neurology1987;37:184-189.
88.
Matilainen R., Pitkanen A., Ruutiainen T., et al: Effect of vigabatrin on epilepsy in mentally retarded patients: A 7-month follow-up study. Neurology1988;38:743-747.
89.
Cosi V., Callieco R., Galimberti CA, et al: Effects of vigabatrin on evoked potentials in epileptic patients . Br J Clin Pharmacol1989;27:61S-68S.
90.
Tartara A., Manni R., Galimberti CA, et al: Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand1992;86:247-251.
91.
Gibbs JM, Appleton RE, Rosenbloom L.: Vigabatrin in intractable childhood epilepsy: A retrospective study . Pediatr Neurol1992;8:338-340.
92.
Rimmer EM, Richens A.: Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol1989;27:275-335.
93.
Luna D., Dulac O., Pajot N., et al: Vigabatrin in the treatment of childhood epilepsies: A single-blind placebo-controlled study. Epilepsia1989;30:430-437.
94.
Herranz JL, Arteaga R., Farr IN, et al: Dose response study of vigabatrin in children with refractory epilepsy. J Child Neurol1991;6(Suppl 2):S45-S51.
95.
del Guidice E., Latte F., Romano A., et al: Vigabatrin in childhood epileptic syndromes. Seizure1992 ; 1 (Suppl A): P7/21.
96.
Rimmer EM, Richens A.: Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy . Lancet1984;1: 189-190.
97.
Gram L., Klosterskov P., Dam M.: Gamma-vinyl-GABA: A double blind placebo-controlled trial in partial epilepsy . Clin Neurol1985;17:262-266.
98.
Loiseau P., Hardenberg JP, Pestre M., et al: Double-blind placebo controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia1986;27:115-120.
99.
Tartara A., Manni R., Galimberti CA, et al: Vigabatrin in the treatment of epilepsy: A double-blind, placebo-controlled study. Epilepsia1986;27:717-723.
100.
Sivenius J. , Ylinen A., Murros K., et al: Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia1987;28:688-692.
101.
Kalviainen R., Aikia M., Mervaala E., et al: Vigabatrin monotherapy in newly diagnosed patients with epilepsy. Epilepsia1993; 34:104.
102.
Chiron C., Dulac O., Beaumont D., et al: Therapeutic trial of vigabatrin in refractory infantile spasms . J Child Neurol1991; 6(Suppl 2):S52-S59.
103.
Livingston JH , Beaumont D., Arzimanoglou A., et al: Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol1989;27:1095-1125.
104.
Dulac O., Chiron C., Luna D., et al: Vigabatrin in childhood epilepsy. J Child Neurol1991;6(Suppl 2):S30-S37.
105.
Uldall P., Alving J., Gram L., et al: Vigabatrin in pediatric epilepsy —an open study. J Child Neurol1991;6(Suppl 2):S38--S44.
106.
Lortie A., Chiron C., Mumford J., et al: The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology1993;43(Suppl 5):S24-S27.
107.
Appleton RE : The role of vigabatrin in the management of infantile epileptic syndromes. Neurology1993 ;43(Suppl 5): S21-S23.
108.
Auerswald G., Schreck W., Dieterich HA: Vigabatrin in therapy-resistant childhood epilepsies. Epilepsia1991;32(Suppl 1):24.
109.
Franzoni E. , Marchiani V., Di Turi RP, et al: Vigabatrin in childhood epilepsy. Seizure1992;1(Suppl A):P7/18.
110.
Pedersen B. : Vigabatrin in the management of drug-resistant epilepsy in patients with tuberous sclerosis. Epilepsia1991; 32(Suppl 1):24.
111.
Brantner S. , Feucht M.: Gamma-vinyl GABA (vigabatrin) in Lennox-Gastaut syndrome—an open trial. Seizure1992 ; 1(Suppl A): P7/05.
112.
Appleton RE , Hughes AP, Beirne M., et al: Vigabatrin in the Landau-Kleffner syndrome. Dev Med Child Neurol1993;35:457-459.
113.
Arteaga R. , Herranz JL, Valdizan EM, et al: Gamma-vinyl GABA (vigabatrin): Relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children . Epilepsia1992;33:923-931.
114.
Rogers D., Bird J., Eames P.: Complex partial status after starting vigabatrin. Seizure1993;2:155-156.
115.
Remy C., Beaumont D.: Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol1989;27:125S-129S.
116.
McGuire AM , Duncan JS, Trimble MR: Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy . Epilepsia1992;33:128-134.
